ライフサイエンスコーパス: adenoviral vector

1 ns, expressing the recombinant OR-I7 from an adenoviral vector.

2 he OSN cilia when expressed in vivo using an adenoviral vector.

3 of the IL-12 gene in a replication-deficient adenoviral vector.

4 fects were observed with the control (empty) adenoviral vector.

5 whether overexpression involved a plasmid or adenoviral vector.

6 hepatocyte growth factor using a recombinant adenoviral vector.

7 Matrigel plugs when compared with a control adenoviral vector.

8 V vector and subsequently with a recombinant adenoviral vector.

9 was overexpressed in SIRT1 LKO mice using an adenoviral vector.

10 ter vaccination with a replication-deficient adenoviral vector.

11 ially created N- and C-terminal-tagged Luman adenoviral vector.

12 by infecting cells with a p220 cDNA-encoding adenoviral vector.

13 dant innate and adaptive immune responses to adenoviral vectors.

14 1alpha and PGC-1beta in C2C12 myotubes using adenoviral vectors.

15 was examined using EGFP- and mRFP-expressing adenoviral vectors.

16 s and neonatal heart cells using plasmid and adenoviral vectors.

17 d packaged the coding sequence of KCNQ4 into adenoviral vectors.

18 s in innate and adaptive immune responses to adenoviral vectors.

19 of magnitude after intratumoral infusion of adenoviral vectors.

20 nt8a, Wnt16, and WISP1 in the synovium using adenoviral vectors.

21 CD80/86 for efficient CD8 T cell priming by adenoviral vectors.

22 th systemic administration of large doses of adenoviral vectors.

23 9 RNA-guided nucleases, and helper-dependent adenoviral vectors.

24 ted efficiently with replication-incompetent adenoviral vectors.

25 in the evaluation of serologically distinct adenoviral vectors.

26 d have cross-reacting potential with non-Ad5 adenoviral vectors.

27 e for the selective chemical modification of adenoviral vectors.

28 ses as well as nonreplicating lentiviral and adenoviral vectors.

29 hPRL-encoding sequence was inserted into an adenoviral vector (16K-Ad).

30 t mice followed by intraluminal injection of adenoviral vectors (3x10(9) pfu in 50 microL) for overex

31 A from a recombinant replication-incompetent adenoviral vector, achieving vaccine production within 3

32 Infection of cardiomyocytes with an adenoviral vector (Ad) encoding A20 inhibited tumor necr

33 Overexpression of activin A with an adenoviral vector (Ad-actbetaA) or treatment with recomb

34 We now report the use of a bicistronic adenoviral vector (Ad-CMV-D2R80a-IRES-HSV1-sr39tk) for l

35 We have constructed a recombinant adenoviral vector (Ad-IRF-1) that infects mammary cells

36 that received mock infected (n=5) or control adenoviral vector (Ad.eGFP; n=6) rejected the allograft

37 We developed a regulatable adenoviral vector (Ad.mhIL-4.TRE.mhIL-13-PE) encoding a

38 Thus, we investigated the hypothesis that adenoviral vectors (Ad) could be delivered from the bare

39 at evaluating the efficacy and safety of an adenoviral vector (Ad2/betaARKct) encoding the carboxyl

40 icroscopy (cryoEM) structural analysis of an adenoviral vector, Ad35F, comprised of an adenovirus typ

41 when delivered with a replication-defective adenoviral vector [Ad5-poIRF7/3(5D)].

42 rat cortical neurons were infected with the adenoviral vector Ad5CMVcatalase and control cells were

43 Recombinant adenoviral vectors (adenovectors) have been subject to v

44 hether treatment with a TNF-alpha-expressing adenoviral vector (adenoviral vector with the murine TNF

45 of a soluble Tie2 receptor (ExTek) using an adenoviral vector (AdExTek) as a Tie2 inhibitor affects

46 acute genetic engineering with a recombinant adenoviral vector (AdMYH7) to genetically titrate beta-M

47 We have constructed adenoviral vectors (Ads) that express structural genes e

48 ssed and CD63 was knocked down in mice using adenoviral vectors AdTIMP1 or AdshCD63, respectively.

49 Inefficient adenoviral vector (AdV)-mediated gene transfer to the ci

50 t liver detargeting and tumor retargeting of adenoviral vectors after coating with synthetic dendrime

51 rus receptor (sCAR-Fc) was expressed from an adenoviral vector and 2 short hairpin RNAs (shRdRp2.4) d

52 expression of both transgenes from a single adenoviral vector and circumvented the recombination pro

53 A vaccine platform transduced with the adenoviral vector and loaded in tandem with the recombin

54 Using both adenoviral vectors and a cell line permanently expressin

55 Here, we use adenoviral vectors and oligonucleotide microarrays to de

56 effects of foreign promoters in recombinant adenoviral vectors and suggest means to improve the util

57 (C93A) were expressed in HLECs, by using an adenoviral vector, and cell cycle progression was assess

58 Human adenoviral vectors are being developed for use in candid

59 y transfection strategies are available, and adenoviral vectors are in clinical trials.

60 Adenoviral vectors are the most widely used agents for v

61 ynergy between tumour necrosis factor and an adenoviral vector as a therapeutically relevant stimulus

62 ansduced with a clinical-grade Ad5f35CMVpp65 adenoviral vector as sources of EBV, Adv, and CMV antige

63 In earlier preclinical studies, a novel adenoviral vector-based vaccine termed AdE1-LMPpoly has

64 We developed an adenoviral vector-based vaccine that contains hemaggluti

65 We used a replication-incompetent, human adenoviral-vector-based, haemagglutinin subtype 5 influe

66 plasmid DNA prime and replication-defective adenoviral vector boost.

67 ced by DNA priming and replication-defective adenoviral vector boosting.

68 ved method for efficient generation of novel adenoviral vectors by using direct cloning.

69 The IRES-based bicistronic adenoviral vector can potentially be used in conjunction

70 Adenoviral vector can selectively and efficiently delive

71 Helper-dependent adenoviral vectors can stably express a therapeutic gene

72 ii) the transfection of CD11c(+) DC using an adenoviral vector carrying a dominant negative SOCS3 gen

73 Infection of human RPE by an adenoviral vector carrying a mutant IkappaB transgene bl

74 a cell monolayer or SNB19 spheroids using an adenoviral vector carrying antisense uPAR and antisense

75 Here, we introduce a helper-dependent adenoviral vector carrying the mifepristone (Mfp)-induci

76 In the treated group, an adenoviral vector carrying the vIL-10 gene was concurren

77 3, and 5 hours after injury) transduced with adenoviral vectors carrying IL8RA, IL8RB, and IL8RA/RB (

78 nd endothelial function in rats treated with adenoviral vectors carrying the CYP4A2 construct.

79 patients were vaccinated using heterologous adenoviral vectors (ChAd3-NSmut and Ad6-NSmut) encoding

80 olated human islets were transduced using an adenoviral vector coding for human EPO or green fluoresc

81 it short-lived, by a single vaccination with adenoviral vectors coding for a liver-stage antigen (ME.

82 In contrast, an adenoviral vector containing a CMV-lacZ reporter was pre

83 t we believe to be a novel dominant-negative adenoviral vector containing a mutant RAD50 gene that si

84 lar injection of recombinant vasohibin or an adenoviral vector containing a vasohibin expression cass

85 sduction in the presence of vitreous with an adenoviral vector containing an IL-12-coding transgene i

86 ammary tumor virus-Cre mice or by delivering adenoviral vector containing Cre to mouse salivary gland

87 A recombinant adenoviral vector containing hGSTA4-4 gene was construct

88 An adenoviral vector containing human SPARC was used to inc

89 demonstrates that systemic therapy with this adenoviral vector containing p53 is feasible.

90 tive knockdown of PKG in cardiomyocytes with adenoviral vector containing short hairpin RNA of PKG al

91 se effects were blunted with infection of an adenoviral vector containing the cDNA for manganese supe

92 An adenoviral vector containing the decorin transgene cause

93 nsduction efficiency of a Group C serotype 5 adenoviral vector containing the fiber domain derived fr

94 AdV-tk, an adenoviral vector containing the herpes simplex virus th

95 feasibility of administering Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene to p

96 n astrocytes of mouse cortex by injection of adenoviral vectors containing a strong and astrocyte-spe

97 Through the use of adenoviral vectors containing either dominant-negative (

98 Adult rat cardiomyocytes were infected with adenoviral vectors containing hPKGIalpha or catalyticall

99 In addition, adenoviral vectors containing the cytomegalovirus immedi

100 lls by a mutant IkappaBalpha super-repressor adenoviral vector decreased the CXCR4 mRNA expression an

101 ts configured with PABT/PEI(PDT)/HL-tethered adenoviral vectors demonstrated both site-specific arter

102 ouse corneas infected with Slurp1-expressing adenoviral vectors displayed reduced signs of inflammati

103 r NF-kappaB p50 protein (A-p50) utilizing an adenoviral vector employing the H1 RNA polymerase III pr

104 ed to increase in both untreated and control adenoviral vector (empty adenovirus type 5 backbone)-tre

105 thway, rats were intravenously injected with adenoviral vector encoding a decoy VEGF receptor (Ad-Flk

106 ritic cells transduced with the adjuvant, an adenoviral vector encoding a dominant negative isoform o

107 Subcutaneous injection of an adenoviral vector encoding a fusion protein of the human

108 T- and B-cell function) were treated with an adenoviral vector encoding adenovirus expressed (Adv)-IK

109 Infection of CMs with an adenoviral vector encoding constitutively active SGK1 (A

110 Intranodally injected adenoviral VEGF-C and adenoviral vector encoding control gene LacZ induced mac

111 neural targets of the VMHdm by injecting an adenoviral vector encoding Cre recombinase (Cre)-regulat

112 Administration of an adenoviral vector encoding Cre recombinase into the sali

113 Finally, gene therapy with an adenoviral vector encoding for the release of the anti-i

114 of intratumoral delivery of a nonreplicating adenoviral vector encoding mda-7/IL-24 (Ad.mda-7) and a

115 Intravitreal injection of an adenoviral vector encoding sFRP1 in mice produced a tite

116 Intracerebroventricular injection of an adenoviral vector encoding superoxide dismutase (Ad-Cu/Z

117 d use of Ad.Egr-TNF, a replication-defective adenoviral vector encoding the cDNA for TNF-alpha under

118 rats by intramyocardial administration of an adenoviral vector encoding thioredoxin-1 (Ad.Trx1).

119 results suggest that local administration of adenoviral vectors encoding betaARKct into the jugular v

120 Adenoviral vectors encoding hepatitis C virus (HCV) nons

121 E1/E3-deleted adenoviral vectors encoding HGF (Ad CMV.HGF), green fluo

122 One week later, adenoviral vectors encoding human IL-10 (AdIL-10) or bet

123 dmixed with skin fibroblasts transduced with adenoviral vectors encoding human IL-2 (hIL-2) and hCD40

124 in vitro experiments with HSCs infected with adenoviral vectors encoding LacZ, Dyn2K44A, or Dyn2WT.

125 ing modified vaccinia virus Ankara (MVA) and adenoviral vectors encoding ME.TRAP can enhance both sho

126 B/c (L. monocytogenes-susceptible) mice with adenoviral vectors encoding natural L. monocytogenes-der

127 s with plasmid DNA and replication-defective adenoviral vectors encoding SIV proteins and then challe

128 ion of XBP1 was knocked down by injection of adenoviral vectors encoding small hairpin RNAs against X

129 and why this is so, we have generated potent adenoviral vectors encoding the endogenous tumor Ags (TA

130 ted that immunizing mice with plasmid DNA or adenoviral vectors encoding this chimeric Gag did not si

131 overexpression mediated by helper-dependent adenoviral vectors exerted significant effects on plaque

132 Finally, an adenoviral vector expressing a dominant-negative Stat3 i

133 In the current study, by using an adenoviral vector expressing a dominant-negative Stat3 i

134 (Notch) osteoblastic cells by transducing an adenoviral vector expressing constitutively active NFATc

135 WT) mice (8-10 weeks old) were injected with adenoviral vector expressing Cre recombinase (Ad-Cre; 2

136 by peri-infarct intramyocardial delivery of adenoviral vector expressing cyclin A2 (n =32) or empty

137 mice treated with a replication incompetent adenoviral vector expressing Dectin-Fc had attenuated gr

138 002 and by transduction of the cells with an adenoviral vector expressing dominant negative Akt.

139 lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17)

140 Intramuscular administration of an adenoviral vector expressing Fstl1 (Ad-Fstl1) accelerate

141 e treated with either the Ad-U(L)20 Rz or an adenoviral vector expressing green fluorescent protein (

142 A helper-dependent adenoviral vector expressing human factor VIII was admin

143 Given previous work showing that an adenoviral vector expressing IFN-beta (Ad.IFNbeta) was h

144 linical trials using a replication-defective adenoviral vector expressing IFN-beta have shown promisi

145 s studied in tumor-bearing mice treated with adenoviral vector expressing IL-12 and agonistic anti-4-

146 in the combination therapy in comparison to adenoviral vector expressing IL-12 or anti-4-1BB treatme

147 ular infection, mice were transduced with an adenoviral vector expressing murine IFN-beta (Ad:IFN-bet

148 To explore this hypothesis, we generated an adenoviral vector expressing MyD88 and show that Ad-MyD8

149 Infarcted hearts injected with adenoviral vector expressing Notch intracellular domain

150 We constructed a helper-dependent adenoviral vector expressing rabbit urokinase plasminoge

151 Transplantation of islets infected with an adenoviral vector expressing sCD40-Ig resulted in allogr

152 ated by prior exposure of chondrocytes to an adenoviral vector expressing sense Bcl-2.

153 ration from tumor spheroids transfected with adenoviral vector expressing siRNA against MMP-2.

154 nduced angiogenesis in mouse tissues with an adenoviral vector expressing VEGF-A(164) (Ad-VEGF-A(164)

155 ypes can be generated in mouse tissues by an adenoviral vector expressing VEGF-A(164).

156 Coadministration of adenoviral vectors expressing a transdominant inhibitor

157 llele (IGF-1R(flox/flox)) were infected with adenoviral vectors expressing Cre.

158 Adenoviral vectors expressing ECSOD, ECSOD(R213G) or bet

159 Prophylactic vaccination with adenoviral vectors expressing either TRP-2 (Ad-Ii-TRP-2)

160 deliver replication-incompetent recombinant adenoviral vectors expressing gene products from several

161 derived from dendritic cells transduced with adenoviral vectors expressing IL-10, IL-4, or Fas ligand

162 rway epithelium by intratracheal delivery of adenoviral vectors expressing RelA (AdRelA) or a dominan

163 by suppressing their endogenous levels using adenoviral vectors expressing specific small interfering

164 ing floxed IGF-1R alleles were infected with adenoviral vectors expressing the Cre recombinase (Ad-Cr

165 ERS-CoV infection by prior transduction with adenoviral vectors expressing the human host-cell recept

166 xpressing Cyclo-oxygenase-2 by 600-fold, and adenoviral vectors expressing the pro-apoptotic gene Bax

167 Initial studies examined PKD through adenoviral vector expression of wild type PKD, constitut

168 l cardiac myocytes, and incorporated into an adenoviral vector for expression in adult cardiac ventri

169 mma mimetic peptides were introduced into an adenoviral vector for intracellular expression.

170 o overcome these hurdles in order to develop adenoviral vectors for combination of systemic oncolytic

171 ne the feasibility of using helper-dependent adenoviral vectors for expression of shRNA in liver, we

172 antibodies, which can selectively immobilize adenoviral vectors for gene delivery of growth factors.

173 ignificant hurdle in clinical application of adenoviral vectors for gene therapy, but it is an attrac

174 optimization and development of HAdV-5-based adenoviral vectors for gene therapy.

175 o, the application of recombinant E1-deleted adenoviral vectors for in vivo gene therapy has been lim

176 However, the utility of adenoviral vectors for vascular gene transfer is limited

177 genital administration of an IL-4-expressing adenoviral vector greatly increased in vivo ESC prolifer

178 Mice that expressed VEGFC from the adenoviral vector had increased lymphatic vessel density

179 An adenoviral vector harboring human GDNF was injected unil

180 We also generated a series of adenoviral vectors harboring mutant NOS II genes that ex

181 Third-generation or "helper-dependent" adenoviral vectors have achieved prolonged recombinant g

182 Recombinant adenoviral vectors have been widely used for gene therap

183 Adenoviral vectors have long been forerunners in the dev

184 Adenoviral vectors have shown great promise as vaccine c

185 ease transgene expression from high-capacity adenoviral vectors (HCAd), but not from first-generation

186 clones, gene correction by helper-dependent adenoviral vector (HDAdV) or Transcription Activator-Lik

187 Because adenoviral vector immunization alone can elicit substant

188 Overexpression of resistin using adenoviral vector in neonatal rat ventricular myocytes w

189 er vaccination with a rhesus macaque-derived adenoviral vector in rhesus macaques enhances mucosal CD

190 carcinoma cells or transiently expressed by adenoviral vector in U251 human glioblastoma cells, inhi

191 Despite the utility of recombinant adenoviral vectors in basic research, their therapeutic

192 ne responses should be considered when using adenoviral vectors in gene therapy and genetic vaccines.

193 Studies with adenoviral vectors in isolated hepatocytes confirm that

194 SK-N-DZ neuroblastoma cells transduced with adenoviral vectors in the presence of versican respond w

195 portant role in innate immune elimination of adenoviral vectors in vivo.

196 s indicate that the use of a capsid-modified adenoviral vector, in combination with TRAIL expression,

197 fects of RII phosphorylation, we constructed adenoviral vectors incorporating mutants which mimic pho

198 of TEFalpha and TEFbeta in A10 cells, using adenoviral vectors, increased expression of endogenous t

199 Elevation of PGC-1alpha in mice via adenoviral vectors increases the levels of heme precurso

200 Chronic central administration of MCH and adenoviral vectors increasing MCH signaling were perform

201 The results showed that vaccination with an adenoviral vector indeed increases activation of mucosal

202 of Mcl-1 using a Mcl-1 antisense-expressing adenoviral vector induced apoptotic cell death, which wa

203 The overexpression of miR-375 with an adenoviral vector inhibited alveolar epithelial trans-di

204 Gax expression using a replication-deficient adenoviral vector inhibited human umbilical vein endothe

205 y of nNOS cDNA using a replication-deficient adenoviral vector into nNOS-/- CGN abolished alcohol-ind

206 oglycan-sarcospan complex when introduced by adenoviral vector into the skeletal muscle of previously

207 Traditionally, construction of adenoviral vectors is complex and time consuming.

208 impediment to successful cancer therapy with adenoviral vectors is the inefficient transduction of ma

209 The long-term persistence of adenoviral vectors may be highly advantageous for their

210 We have examined the ability of adenoviral vector mediated local production of sCD40-imm

211 Herein we show that adenoviral vectors mediated effective NOS II gene transf

212 itro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT

213 y in mouse neuroblastoma Neuro2a cells after adenoviral vector-mediated delivery of an adFNDI mutant

214 stems, Rac1 activity was manipulated through adenoviral vector-mediated delivery of constitutively ac

215 s were exposed to inhibitors or subjected to adenoviral vector-mediated gene manipulations and then t

216 m-dependent action was further studied using adenoviral vector-mediated gene transfer of dominant neg

217 at enforced expression of wild-type 101F6 by adenoviral vector-mediated gene transfer significantly i

218 Adenoviral vector-mediated in vivo transduction was used

219 c effects of gene deletion were addressed by adenoviral vector-mediated rescue of the neurophysiologi

220 nd suggest that E1B 19K-deleted, replicating adenoviral vectors might induce greater inflammatory res

221 ression of periostin in cell culture, via an adenoviral vector, nor stimulation with recombinant prot

222 Overexpression of an adenoviral vector of native IRS1, IRS2, and Akt dominant

223 Prior immunization with adenoviral vectors of alternative human or simian seroty

224 ous prime boost regimens based on E1-deleted adenoviral vectors of different serotypes expressing the

225 cts of forced expression of PPARgamma via an adenoviral vector on morphologic and biochemical feature

226 essed by interstitial cells infected with an adenoviral vector or by tumor cells, upsets the normal c

227 cultured keratinocytes by transduction with adenoviral vectors or inhibited with PKC-selective inhib

228 king the kappa opioid receptor (kappaOR) and adenoviral vectors overexpressing or silencing kappaOR w

229 gnificantly reduced following infection with adenoviral vectors overexpressing SOCS1.

230 Using the adenoviral vector paradigm, there are three broad strate

231 aft HIF-1alpha overexpression induced via an adenoviral vector prolonged airway microvascular perfusi

232 that a genetically engineered RSV-F-encoding adenoviral vector provides protective immunity against R

233 Recombinant adenoviral vectors (rAds) are lead vaccine candidates fo

234 Recombinant adenoviral vectors (rAds) are the most potent recombinan

235 and early signaling response to recombinant adenoviral vectors (rAdV).

236 Treatment efficacy of the adenoviral vectors released from the MMP responsive SELP

237 cell activation and function in response to adenoviral vectors remain largely undefined.

238 What regulate(s) potent B cell response to adenoviral vectors remains incompletely defined.

239 of immunocompetent mice with low doses of an adenoviral vector resulted in persistent HBV infection;

240 A-B35 expression at physiological levels via adenoviral vector resulted in significantly increased en

241 ase and mitochondrial-targeted catalase with adenoviral vectors reversed the dicumarol-induced cytoto

242 Previous studies have described the adenoviral vector RGDTKSSTR with a double-expression cas

243 and/or mitochondrial targeted catalase using adenoviral vectors significantly protected PC-3 cells fr

244 er vaccination with a rhesus macaque-derived adenoviral vector (simian adenovirus 7 [SAdV-7]) enhance

245 cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (

246 cancer cell line (HT29) transfected with an adenoviral vector that expressed Ad VP16hLXRalpha, compa

247 r by injection of RPE cells infected with an adenoviral vector that expressed CTGF.

248 hepatic c-myc in c-myc(fl/fl) mice using an adenoviral vector that expresses Cre recombinase.

249 inhibition of NF-kappaB by infection with an adenoviral vector that expresses the IkappaBalpha super-

250 the fiber protein produced a ligand-modified adenoviral vector that mediated 14-fold-better transduct

251 njection, and suggest that already developed adenoviral vectors that encode secreted factors could po

252 Oncolytic adenoviral vectors that express immunostimulatory transg

253 elial NKCC1 and chloride secretion utilizing adenoviral vectors that express shRNAs targeting human P

254 , we treated Apoe-/- mice with apoE-encoding adenoviral vectors that induce plaque regression, and in

255 icient activation of host B cell response to adenoviral vectors that leads to the generation of prote

256 itreous injection of RPE cells infected with adenoviral vectors that overexpress CTGF induced fibroti

257 using plasmid cotransfection or bicistronic adenoviral vectors, the retargeted H proteins could medi

258 Following transduction with E1-deficient adenoviral vectors, these CTLs produced infectious virus

259 g hydrodynamic injection or high doses of an adenoviral vector; these lead to clearance of HBV.

260 this study, we used a tetracycline-inducible adenoviral vector to express a truncated CBF-B subunit,

261 This trial used a prototype adenoviral vector to express aquaporin-1 (AQP1), presuma

262 NTS GABAergic neurons were targeted using an adenoviral vector to express enhanced green fluorescent

263 in preBotC astrocytes bilaterally (using an adenoviral vector to specifically express tetanus toxin

264 o this study, the authors used a recombinant adenoviral vector to transiently introduce OMP into olfa

265 lymphocytic choriomeningitis virus model and adenoviral vectors to compare a vaccine expressing unmod

266 These studies indicate the usefulness of adenoviral vectors to deliver leishmanial antigens in a

267 s the feasibility of using recombinant human adenoviral vectors to detect nodal metastases in a human

268 We used adenoviral vectors to express Nor-1 in normal liver (Ad/

269 lls (HUVEC) were transduced with recombinant adenoviral vectors to express wild-type, constitutively

270 llular protein that restricts the ability of adenoviral vectors to infect cancer cells.

271 r could be achieved by direct application of adenoviral vectors to the epicardial surface, use of pol

272 We initiated HBV infection via an adenoviral vector transferring a 1.3-fold overlength HBV

273 hese data implicate versican G1 in enhancing adenoviral vector transgene expression in a hyaluronic a

274 hanism of hyaluronan-mediated enhancement of adenoviral vector transgene expression.

275 can either enhance or diminish apoptosis in adenoviral vector-treated and TNF-treated hepatocytes, i

276 intracerebroventricular (ICV) delivery in an adenoviral vector triggers the addition of new neurons t

277 Most engineered adenoviral vectors use a heterologous promoter to transc

278 Adenoviral vectors used in gene therapy induce inflammat

279 Vaccination with potent HCV adenoviral vectored vaccines fails to restore T-cell imm

280 te that coformulation of Ab and poxviral- or adenoviral-vectored vaccines induces significantly incre

281 increase in hepatic F.IX expression from the adenoviral vector was achieved despite in vitro T cell r

282 cking Tie-2 receptor-interaction pathway, an adenoviral vector was used to deliver a recombinant sing

283 We demonstrate that the yield of adenoviral vectors was lower in over-confluent 293 cells

284 Using an adenoviral vector, we generated mice overexpressing smad

285 Using RNAi and a new generation of adenoviral vector, we have silenced hepatic SREBP-1 in n

286 To address this context problem for adenoviral vectors, we have engineered a "context-specif

287 Adenoviral vectors were also injected directly into tumo

288 ructurally different replication-incompetent adenoviral vectors were engineered that express (1) an i

289 Adenoviral vectors were generated for TGFbetaRI (AdTGFbe

290 Adenoviral vectors were used to express Slurp1 in cornea

291 Adenoviral vectors were used to induce transient overexp

292 Adenoviral vectors were used to overexpress fibulin-3 wi

293 systemic administration of an E1/E3-deleted adenoviral vector, which is known to induce a cytotoxic

294 Helper-dependent adenoviral vectors will be useful agents for vascular ge

295 We used an adenoviral vector with a catecholaminergic-selective pro

296 orated into a replication-incompetent type-5 adenoviral vector with a cytomegalovirus promoter.

297 s A1 and A2 were fluorescently labeled by an adenoviral vector with noradrenergic-specific promoter.

298 th a TNF-alpha-expressing adenoviral vector (adenoviral vector with the murine TNF-alpha transgene un

299 wo triple immunization vaccine regimens with adenoviral vectors with E1 deleted expressing Gag of hum

300 f ONYX-015 (dl1520), a replication-selective adenoviral vector, with E1b deleted, for patients with m